Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants.

J I Weitz1, S M Bates

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada. jweitz@thrombosis.hhscr.org

Journal of Thrombosis and Haemostasis : JTH
|August 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physicochemical and functional assessment of messenger RNA 5'Cap-end impurities under forced degradation conditions.

Molecular therapy. Nucleic acids·2025
Same author

Relationship between Surgery and Trauma and Risk of Recurrence in Patients with an Associated First Venous Thrombotic Event: A Nested Case-Control Study.

Thrombosis and haemostasis·2025
Same author

COVID-19 in thrombosis research: An editorial perspective.

Thrombosis research·2021
Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020
Same author

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.

Thrombosis research·2019
Same author

Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke.

Journal of thrombosis and haemostasis : JTH·2018
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Growth differentiation factor-15 and bleeding risk in patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Physiological Anticoagulant Deficiencies: Pathogenesis, Diagnosis, and Clinical Implications.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

New anticoagulant drugs, including fondaparinux and oral direct thrombin inhibitors, offer alternatives to heparin and warfarin for preventing and treating thromboembolism. Some new oral agents show promise but require further investigation for potential side effects.

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Heparin and warfarin have limitations in anticoagulation therapy.
  • Development of novel anticoagulants is crucial for managing thromboembolic disorders.
  • Pentasaccharide analogs and oral direct inhibitors represent new therapeutic avenues.

Purpose of the Study:

  • To review novel parenteral and oral anticoagulant agents.
  • To discuss anticoagulants in advanced clinical testing stages.
  • To highlight advancements beyond traditional therapies like warfarin.

Main Methods:

  • Review of scientific literature on anticoagulant drug development.
  • Focus on synthetic pentasaccharides (fondaparinux, idraparinux).
  • Examination of oral anticoagulants targeting thrombin, factor Xa, and factor IXa.

Related Experiment Videos

Main Results:

  • Fondaparinux is approved for venous thromboembolism (VTE) prevention and treatment.
  • Idraparinux is under investigation for VTE and atrial fibrillation.
  • Ximelagatran, an oral direct thrombin inhibitor, is effective but has potential liver enzyme elevations.

Conclusions:

  • Novel anticoagulants offer streamlined therapy with potential for reduced monitoring.
  • Further research is needed to assess long-term safety and efficacy of new agents, particularly oral direct inhibitors.
  • These advancements aim to improve outcomes in patients with venous and arterial thromboembolism.